Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older
• People who have been diagnosed with metastatic non-small cell lung cancer that has spread to the membranes surrounding the brain or spinal cord (called leptomeningeal metastasis), confirmed by tissue or cell testing, and whose cancer has stopped responding to TKI (targeted therapy) treatment
• People whose cancer has a specific genetic change confirmed by an accredited lab — this includes EGFR mutation, ALK fusion, ROS1 fusion, RET fusion, BRAF mutation, NTRK fusion, or KRAS mutation
• People whose blood counts and organ function (such as liver and kidneys) are at an adequate level
• People who agree to receive a chemotherapy drug called pemetrexed delivered directly into the spinal fluid (intrathecal injection)
• People with a general health/activity level rated as ECOG 0, 1, or 2 — meaning they are able to carry out at least some daily activities (confirm with trial site)
• People whose doctors expect them to survive for at least 12 weeks

Who may not be able to join:

• People who have previously received pemetrexed delivered into the spinal fluid (intrathecal pemetrexed)
• People who have had radiation therapy within 14 days before starting the trial, or who are still experiencing side effects from radiation — though some specific types of radiotherapy (chest, palliative, or stereotactic) may be allowed if completed at least 7 days before starting (confirm with trial site)
• People who have spinal cord compression or meningeal metastasis of a type that would exclude them (confirm with trial site for clarification)
• People who have had another cancer within the past 2 years
• People still experiencing side effects (other than hair loss) from previous treatments such as chemotherapy or radiotherapy, rated above a mild level
• People who have had a stroke or bleeding in the brain within the 6 months before starting the trial
• People with severe or poorly controlled conditions such as uncontrolled high blood pressure or active bleeding
• People with ongoing or active infections, including hepatitis B, hepatitis C, HIV, or COVID-19
• People with certain heart-related diseases or abnormalities (confirm with trial site for full details)
• People with a history of certain lung conditions, including interstitial lung disease, radiation-related lung inflammation requiring steroid treatment, or immune-related lung inflammation from immunotherapy
• People who have severe ongoing nausea and vomiting, chronic gut disease, difficulty swallowing tablets, or poor absorption of medication due to previous bowel surgery — specifically affecting the study drugs sunvozertinib or anlotinib
• People who have received a live vaccine within 2 weeks before starting the trial
• People who are pregnant or breastfeeding
• People who are known to be allergic to any of the study drugs or their ingredients
• People whom the trial investigators consider unsuitable for other reasons

Important: Always verify eligibility with the trial site directly before applying.